NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

作者：Al B. Benson, Michael I. D’Angelica, Thomas A. Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert A. Anders, Chandrakanth Are, Melinda Bachini, David C. Binder, Mitesh J. Borad, Christopher L. Bowlus, Daniel B. Brown, Adam M. Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan M. Cloyd, Anne M. Covey, Evan S. Glazer, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Lawrence J. Jennings, Robin Kate Kelley, Robin D. Kim, Matthew H. Levine, Manisha Palta, James O. Park, Steven S. Raman, Sanjay S. Reddy, Sean M. Ronnekleiv‐Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean‐Nicolas Vauthey, Alan P. Venook, Adam C. Yopp, Nicole R. McMillian, Ryan Schonfeld, Cindy Hochstetler · 发表于：Journal of the National Comprehensive Cancer Network · 年份：2023 · DOI：10.6004/jnccn.2023.0035 · 被引用次数：213 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Genetic factors in colorectal cancer、Colorectal Cancer Treatments and Studies

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.